In the following video, Motley Fool health care bureau chief Brenton Flynn highlights 2012 as a big year for the four biggest biotechs, but the biggest of the four, Amgen , tends to get lost in the mix. He shows us some of the biggest trends in the company's portfolio and pipeline that may be holding that multiple down at the moment. He also discusses information from the company's presentation at the JPMorgan conference this week about its pipeline that may be a needle-mover for the company's multiple back upwards.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. Make sure you start 2013 with a bang and get the inside scoop on what Motley Fool Superinvestor David Gardner will be buying this year. He's crushed the market in his Stock Advisor and Rulebreakers portfolios for years, and now I invite you to a personal tour of his flagship stock picking service: Supernova. Just click here now for instant access.
The article The Most Neglected Big Biotech originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.